WO2013061588A1 - Transdermally absorbed preparation - Google Patents

Transdermally absorbed preparation Download PDF

Info

Publication number
WO2013061588A1
WO2013061588A1 PCT/JP2012/006829 JP2012006829W WO2013061588A1 WO 2013061588 A1 WO2013061588 A1 WO 2013061588A1 JP 2012006829 W JP2012006829 W JP 2012006829W WO 2013061588 A1 WO2013061588 A1 WO 2013061588A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
adhesive layer
sensitive adhesive
imidafenacin
carbon atoms
Prior art date
Application number
PCT/JP2012/006829
Other languages
French (fr)
Japanese (ja)
Inventor
勝幸 猪尾
大樹 高野
渡邉　正人
範洋 金山
Original Assignee
杏林製薬株式会社
帝國製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杏林製薬株式会社, 帝國製薬株式会社 filed Critical 杏林製薬株式会社
Priority to JP2013540656A priority Critical patent/JP5995112B2/en
Publication of WO2013061588A1 publication Critical patent/WO2013061588A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a percutaneous absorption preparation containing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof as an active ingredient.
  • imidafenacin is a compound with selective M1 / M3 muscarinic receptor antagonistic activity, for example, frequent urination and urine associated with overactive bladder Known as an incontinence drug.
  • transdermal preparations have been proposed (for example, Patent Documents 1 and 2).
  • imidafenacin can be easily administered even to elderly people.
  • a temporary increase in blood concentration which may occur in the case of oral administration, can be suppressed.
  • the absorbability of drugs by transdermal administration is lower than that of oral administration, etc. It is often difficult to ensure the necessary blood concentration. Therefore, the drugs that can be administered in the dosage form of the transdermal preparation are limited. Imidafenacin also has very low absorbability from the skin, and therefore, improvement in transdermal absorbability when administered as a transdermally absorbable preparation is required.
  • the present invention has been made based on such circumstances, and has excellent transdermal absorbability with respect to 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof. It aims at providing the percutaneous absorption type formulation which shows this.
  • transdermally absorbable preparation according to any one of 1) to 3), wherein the acrylic pressure-sensitive adhesive layer further contains an ester of a fatty acid having 6 to 20 carbon atoms.
  • another embodiment of the present invention provides 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyl containing an acrylic pressure-sensitive adhesive, oleic acid, and a carboxylic acid having 2 to 10 carbon atoms
  • the present invention relates to a composition that promotes transdermal absorption of an amide or a pharmaceutically acceptable salt thereof.
  • the said composition can be used as a composition which comprises the adhesive layer of a percutaneous absorption type formulation, for example.
  • a percutaneous absorption preparation having excellent percutaneous absorption for 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof. can do.
  • the percutaneous absorption type preparation of this embodiment has a support and an acrylic pressure-sensitive adhesive layer (hereinafter also simply referred to as a pressure-sensitive adhesive layer) containing an acrylic pressure-sensitive adhesive formed on the surface of the support.
  • the pressure-sensitive adhesive layer contains 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the transdermal preparation refers to a pharmaceutical dosage form that is affixed to the skin and absorbs the drug into the body through the skin. Drugs introduced into the body through the skin are absorbed, for example, into capillaries and delivered to the site of action according to blood flow.
  • blended with an acrylic adhesive layer other than the imidafenacin which is an active ingredient is generally called an additive.
  • Additives include oleic acid, carboxylic acids having 2 to 10 carbon atoms, and other ingredients (capric acid and crotamiton, esters of fatty acids having 6 to 20 carbon atoms, and / or as required) Or other ingredients).
  • the ratio of each component contained in the pressure-sensitive adhesive layer to the total components of the pressure-sensitive adhesive layer is based on the total mass of the pressure-sensitive adhesive layer composed of the acrylic pressure-sensitive adhesive, imidafenacin, and additives. It means that. However, the total mass of the reference pressure-sensitive adhesive layer does not include an organic solvent that may be used during production.
  • Acrylic adhesive which comprises an adhesive layer
  • Acrylic pressure-sensitive adhesives are, for example, acrylic ester homopolymers formed from one type of acrylic ester, copolymers formed from two or more types of acrylic ester, acrylic esters and other functional monomers. It can be formed from a copolymer with a monomer, or a mixture thereof.
  • Acrylic acid esters are, for example, (meth) acrylic acid methyl ester, (meth) acrylic acid ethyl ester, (meth) acrylic acid butyl ester, (meth) acrylic acid pentyl ester, (meth) acrylic acid hexyl ester, (meth) Acrylic heptyl ester, (meth) acrylic acid octyl ester, (meth) acrylic acid nonyl ester, (meth) acrylic acid decyl ester, or the like can be used.
  • Functional monomers capable of forming a copolymer with an acrylic ester include, for example, hydroxyl group-containing monomers such as (meth) acrylic acid hydroxyethyl ester, (meth) acrylic acid hydroxypropyl ester, (meth) Amide group-containing monomers such as acrylamide and dimethyl (meth) acrylamide, or carboxyl group-containing monomers such as (meth) acrylic acid, itaconic acid, and maleic acid can be used.
  • acrylic adhesive acrylic acid / octyl acrylate ester copolymer, 2-ethylhexyl acrylate / 2-ethylhexyl methacrylate / dodecyl methacrylate copolymer, or 2-ethylhexyl acrylate / vinyl pyrrolidone acrylate A copolymer or the like can be used.
  • the ratio of the acrylic pressure-sensitive adhesive with respect to all components blended in the pressure-sensitive adhesive layer is not particularly limited, but can be, for example, 50 to 90% by mass (preferably 50 to 80% by mass).
  • the pressure-sensitive adhesive layer contains imidafenacin as an active ingredient, specifically, 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof.
  • Imidafenacin may be blended either in a dissolved form or in a mixture of a dissolved form and a non-dissolved form.
  • the dissolved type means a state in which imidafenacin is completely dissolved in the pressure-sensitive adhesive layer, and specifically refers to a state in which imidafenacin crystals are not observed visually or with an optical microscope in the pressure-sensitive adhesive layer.
  • the non-dissolving type means that imidafenacin is present in the pressure-sensitive adhesive layer in a crystalline or non-crystalline state.
  • the dissolved form of imidafenacin is absorbed into the body through the skin.
  • Insoluble imidafenacin is not directly absorbed into the body, but changes into dissolved form as the dissolved imidafenacin decreases with percutaneous absorption. That is, undissolved imidafenacin acts as a source of dissolved imidafenacin.
  • imidafenacin contained in the pressure-sensitive adhesive layer is preferably a dissolution type from the viewpoint of quality stability such as rapid transdermal absorbability and skin adhesiveness.
  • Examples of pharmaceutically acceptable salts of 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide include inorganic acid salts such as hydrochloride, sulfate, or hydrobromide, Or organic acid salts such as maleate, fumarate, acetate, oxalate, tartrate, or benzenesulfonic acid.
  • the ratio of imidafenacin to the total components blended in the pressure-sensitive adhesive layer is not particularly limited, but can be, for example, 1 to 30% by mass (preferably 2 to 20% by mass).
  • the pressure-sensitive adhesive layer contains oleic acid and a carboxylic acid having 2 to 10 carbon atoms.
  • the transdermal absorbability of imidafenacin can be enhanced.
  • Oleic acid acts, for example, as a solubilizer that dissolves imidafenacin in an acrylic adhesive.
  • the carboxylic acid having 2 to 10 carbon atoms acts as a solubilizer, for example, like oleic acid.
  • Examples of the carboxylic acid having 2 to 10 carbon atoms include acetic acid, propionic acid, butyric acid, pentanoic acid, and heptanoic acid.
  • a hydroxy acid which is a carboxylic acid having an alcoholic or phenolic hydroxyl group can also be used.
  • the hydroxy acid include lactic acid, tartaric acid, and citric acid. In this embodiment, it is preferable to use a hydroxy acid, and it is more preferable to use lactic acid from the viewpoint of the solubility of imidafenacin.
  • the ratio of oleic acid and carboxylic acid having 2 to 10 carbon atoms to the total components blended in the adhesive layer is not particularly limited.
  • the proportion of oleic acid can be 2 to 20% by mass (preferably 5 to 15% by mass) with respect to the total components blended in the pressure-sensitive adhesive layer.
  • the proportion of the carboxylic acid having 2 to 10 carbon atoms can be 0.5 to 30% by mass (preferably 1 to 20% by mass) with respect to all the components blended in the pressure-sensitive adhesive layer.
  • the acrylic adhesive layer containing imidafenacin further contains capric acid and crotamiton in addition to oleic acid and carboxylic acid having 2 to 10 carbon atoms. It is preferable to do.
  • Capric acid acts as a solubilizer, for example, like oleic acid and carboxylic acids having 2 to 10 carbon atoms.
  • crotamiton acts as an absorption promoter for imidafenacin into the body, for example.
  • the transdermal absorbability of imidafenacin can be further enhanced by containing capric acid and crotamiton in the adhesive layer.
  • the pressure-sensitive adhesive layer of the transdermal preparation containing imidafenacin is described later in addition to carboxylic acid having 2 to 10 carbon atoms such as oleic acid and lactic acid, capric acid and crotamiton. It further contains an ester of a fatty acid having 6 to 20 carbon atoms, such as isopropyl myristate.
  • the ratio of capric acid and crotamiton to the total component blended in the pressure-sensitive adhesive layer is not particularly limited.
  • the ratio of capric acid is 0.1 to 20% by mass (preferably, the total component blended in the pressure-sensitive adhesive layer). 0.5 to 15% by mass).
  • the ratio of crotamiton can be 0.1 to 10% by mass (preferably 0.5 to 10% by mass) with respect to the total components blended in the pressure-sensitive adhesive layer.
  • an ester of a fatty acid having 6 to 20 carbon atoms contains imidafenacin.
  • the physical properties of the pressure-sensitive adhesive layer can be optimized, and the transdermal absorbability of imidafenacin can be further increased.
  • An ester of a fatty acid having 6 to 20 carbon atoms acts, for example, as a softening agent that increases the tackiness of an acrylic pressure-sensitive adhesive.
  • Examples of the fatty acid ester having 6 to 20 carbon atoms include isopropyl myristate, isopropyl palmitate, and oleyl oleate. In this embodiment, it is preferable to use isopropyl myristate.
  • the ratio of the fatty acid ester having 6 to 20 carbon atoms to the total components blended in the pressure-sensitive adhesive layer can be 2 to 50% by mass, preferably 5 to 40% by mass.
  • the pressure-sensitive adhesive layer may further contain other components as additives.
  • other components include one or more of other solubilizers, other softeners, other absorption enhancers, skin irritation mitigators, and antioxidants.
  • Soluble agents include higher fatty acid esters (such as isopropyl palmitate or oleyl oleate), higher alcohols (such as lauryl alcohol, isopropanol, isostearyl alcohol, octyldodecanol, or oleyl alcohol), fatty acids (isostearic acid, lauric acid, Adipic acid, sebacic acid, or myristic acid), dibasic acid diesters (diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, etc.), triacetin, benzyl alcohol, cetyl lactate, octyldodecyl lactate, liquid paraffin, or these The mixture of 2 or more types of these can be mentioned.
  • higher fatty acid esters such as isopropyl palmitate or oleyl oleate
  • higher alcohols such as lauryl alcohol, isopropanol, isostearyl alcohol, oc
  • paraffin oil such as liquid paraffin
  • animal oil such as squalane and squalene
  • almond oil olive oil
  • camellia oil castor oil
  • tall oil peanut oil and other vegetable oils
  • silicone oil polybutene
  • medium chain fatty acid triglyceride Mention may be made of glyceryl monostearate, isopropyl myristate, diisopropyl adipate, dipropylene glycol or mixtures of two or more thereof.
  • Absorption accelerators include triacetin, fatty acids or fatty alcohols (lauric acid, myristic acid, oleyl alcohol, isopropanol, lauryl alcohol, dipropylene glycol, propylene glycol, etc.), fatty acid esters (glyceryl monolaurate, glyceryl monoole) Cetyl lactate, octyl dodecyl lactate, glycerol monolaurate, glycerol monooleate, propylene glycol monolaurate, propylene glycol monooleate, sorbitan monolaurate, or sorbitan monooleate), or a mixture of two or more of these Can be mentioned.
  • fatty acids or fatty alcohols lauric acid, myristic acid, oleyl alcohol, isopropanol, lauryl alcohol, dipropylene glycol, propylene glycol, etc.
  • fatty acid esters glyceryl monolaurate, glyce
  • Examples of the skin irritation mitigating agent include glycerin, allantoin, antihistamines (diphenhydramine, etc.), anti-inflammatory agents (glycyrrhetinic acid, etc.), steroids, or a mixture of two or more of these.
  • antioxidant examples include dibutylhydroxytoluene (BHT), DL- ⁇ -tocopherol, ascorbyl palmitate, or a mixture of two or more thereof.
  • BHT dibutylhydroxytoluene
  • DL- ⁇ -tocopherol DL- ⁇ -tocopherol
  • ascorbyl palmitate or a mixture of two or more thereof.
  • additives may also be included as additives.
  • petroleum resin Quinton or Alcon etc.
  • surfactant polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene sorbite fatty acid ester (polysorbate 20, polysorbate 60, Polysorbate 80 or polyoxyethylene sorbitan monolaurate), polyoxyethylene fatty acid ester (polyoxyl 40 stearate), sorbitan fatty acid ester (sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate, or sorbitan sesquioleate) Etc.), self-emulsifying type glyceryl monostearate, glyceryl monostearate, sorbitan monostearate, sucrose fatty acid ester, macrogol 400, lauromacro Sodium phosphate, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene nonylphenyl ether, polyoxy
  • the transdermal preparation of this embodiment can be produced by forming an acrylic pressure-sensitive adhesive layer on a support.
  • the pressure-sensitive adhesive layer is preferably covered with a release liner for the purpose of protecting the pressure-sensitive adhesive layer until it is used.
  • the manufacturing method of the transdermally absorbable preparation of the present embodiment is not particularly limited, and can be appropriately selected by those skilled in the art.
  • the transdermally absorbable preparation of this embodiment can be produced by a method generally called a hot melt method or a method called a solvent method. When based on the hot melt method, for example, a mixture (base component) of imidafenacin, an additive, and an acrylic pressure-sensitive adhesive is melted by heat and applied to a release film or a support to form a pressure-sensitive adhesive layer.
  • a transdermal preparation is obtained by bonding the formed pressure-sensitive adhesive layer to a support or a release film.
  • a mixture of imidafenacin, an additive, and an acrylic pressure-sensitive adhesive is dissolved in an organic solvent such as methanol, ethanol, ethyl acetate, chloroform, or hexane, and a release film or a support is obtained. Extend and apply on the body. Next, the solvent is removed by drying to form an adhesive layer. Subsequently, a transdermal preparation is obtained by bonding the formed pressure-sensitive adhesive layer to a support or a release film.
  • size and thickness of an adhesive layer are not specifically limited, Those skilled in the art can set suitably.
  • the material for the support of the transdermal preparation of the present embodiment is not particularly limited, and can be appropriately set by those skilled in the art.
  • a stretchable or non-stretchable support can be used.
  • it can be selected from cloth, non-woven fabric, polyurethane, polyester, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate (PET), aluminum sheet, or a composite material thereof.
  • the material of the release film is not particularly limited and can be appropriately selected by those skilled in the art.
  • Specific examples include a polyethylene film, a PET film, or a polypropylene film obtained by silicon coating.
  • the transdermally absorbable preparation of the present embodiment includes, for example, frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, chronic obstructive pulmonary disease (COPD), Alternatively, it is useful as a preventive and / or therapeutic agent for irritable bowel syndrome (IBS).
  • OAB overactive bladder
  • COPD chronic obstructive pulmonary disease
  • IBS irritable bowel syndrome
  • the affixing site is not particularly limited, and is, for example, the back of the ear, the abdomen such as the arm or lower abdomen, the chest, the back, the waist, the buttocks, the inner side of the thigh, or the legs such as the calf.
  • the amount of imidafenacin contained in the pressure-sensitive adhesive layer is not particularly limited, and the disease to be prevented or treated, the size of the pressure-sensitive adhesive layer, the administration time, or the target blood concentration of imidafenacin
  • about 0.1 mg to about 30 mg can be blended in the preparation or in a single dose.
  • the transdermal absorbability of imidafenacin can be improved by containing oleic acid and a carboxylic acid having 2 to 10 carbon atoms in addition to imidafenacin in the acrylic adhesive layer. it can. Moreover, the transdermal absorbability of imidafenacin can be further improved by containing capric acid and crotamiton in the adhesive layer. Furthermore, the transdermal absorption of imidafenacin can be further enhanced by containing an ester of a fatty acid having 6 to 20 carbon atoms in the adhesive layer.
  • the transdermal preparation of this embodiment for example, imidafenacin can be efficiently absorbed into the circulating blood through the skin. .
  • side effects that can occur with the rapid increase in blood concentration seen in oral administration can be avoided. Therefore, the transdermally absorbable preparation of this embodiment is very useful as a preventive and / or therapeutic drug for frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, COPD, IBS, and the like.
  • OAB overactive bladder
  • transdermally absorbable preparation of the present invention is not limited to the form described in the examples.
  • Example 1 9 g of 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide, 3 g of lactic acid, 7 g of oleic acid and 0.9 g of capric acid were dissolved in 100 g of methanol. To this solution, 17 g of isopropyl myristate and 2 g of crotamiton were added and mixed well to obtain a main agent solution. Thereafter, the main agent solution was added to 305.5 g of an acrylic acid / octyl acrylate copolymer / ethyl acetate solution having a solid concentration of 20% (61.1 g as the weight of the adhesive) and mixed well to prepare an adhesive solution.
  • Example 1 Apply the adhesive solution to a 75um PET film using a comma doctor so that the weight of the paste after drying is about 80g / m 2 and dry for 10 minutes at a temperature of about 80 ° C. A layer was formed. The formed pressure-sensitive adhesive layer and a support (15 ⁇ m thick PET film) were bonded together to obtain a transdermal absorption preparation of Example 1.
  • Example 2 to 4 and Comparative Examples 1 to 14 Transdermal absorption preparations of Examples 2 to 4 and Comparative Examples 1 to 14 were prepared in the same manner as in Example 1, except that the ratio of the components contained was changed. The amounts of components contained in the pressure-sensitive adhesive layer in Examples and Comparative Examples are shown in FIG.
  • [In vitro rat skin permeability test method] Franz-type cell in which the abdominal skin ( ⁇ 15mm) of HWY male hairless rats (10-11 weeks old) (weight 260-280g) was peeled off, and 37 ° C hot water was circulated around the outer periphery with the dermis side as the receptor layer side (Open area: 1.77 cm 2 ). Next, the percutaneous absorption preparations ( ⁇ 14 mm) of Examples and Comparative Examples were attached to the stratum corneum side of the skin. A PBS buffer solution (pH 7.4) was used as the receptor solution, and the receptor solution was sampled over time. The concentration of imidafenacin in the sampled receptor fluid was measured by the UPLC (Ultra Performance Liquid Chromatography) method under the following measurement conditions.
  • UPLC Ultra Performance Liquid Chromatography
  • the cumulative drug permeation amount per 1 cm 2 of the preparation at each sampling point was calculated ( ⁇ g / cm 2 ), and the relationship between time and cumulative drug permeation amount was graphed. Thereafter, a correlation line of the cumulative drug permeation amount was calculated from the graph, and the slope thereof was defined as a FLUX value that is a drug permeation rate.
  • FLUX Amount of transdermal drug absorbed per hour that is transdermally absorbed from an area of 1 cm 2 of the formulation after application
  • the obtained FLUX value is shown in FIG.
  • the percutaneous absorption preparations of Examples 1 to 4 all showed higher imidafenacin percutaneous absorption than the percutaneous absorption preparation of the comparative example.
  • the percutaneous absorption preparation of Example 1 containing capric acid and crotamiton was confirmed to have a higher percutaneous absorption than the other Examples.
  • the transdermally absorbable preparation of the present invention can prevent, for example, frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, chronic obstructive pulmonary disease (COPD), and irritable bowel syndrome (IBS). Useful for treatment.
  • OAB overactive bladder
  • COPD chronic obstructive pulmonary disease
  • IBS irritable bowel syndrome

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[Problem] To provide a transdermally absorbed preparation having excellent transdermal absorbability of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof contained therein. [Solution] A transdermally absorbed preparation comprising a support and an acrylic adhesive agent layer that is formed on the surface of the support and contains 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, wherein the acrylic adhesive agent layer additionally contains oleic acid and a carboxylic acid having 2-10 carbon atoms.

Description

経皮吸収型製剤Transdermal preparation
　本発明は、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドまたは薬学的に許容可能なその塩を有効成分として含有する経皮吸収型製剤に関する。 The present invention relates to a percutaneous absorption preparation containing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof as an active ingredient.
　4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミド（イミダフェナシン）は、選択的M1/ M3ムスカリン受容体拮抗作用を有する化合物であり、例えば過活動膀胱に伴う頻尿・尿失禁治療薬として知られている。
　イミダフェナシンの投与剤形としては、経口固形製剤のほか、経皮吸収型製剤が提案されている（例えば特許文献1および2）。経皮吸収型製剤の場合、例えば高齢者等であってもイミダフェナシンの投与が容易である。また、経口投与などの場合において生じることもある、一時的な血中濃度の上昇を抑えることもできる。 4- (2-Methyl-1-imidazolyl) -2,2-diphenylbutyramide (imidafenacin) is a compound with selective M1 / M3 muscarinic receptor antagonistic activity, for example, frequent urination and urine associated with overactive bladder Known as an incontinence drug.
As dosage forms of imidafenacin, in addition to oral solid preparations, transdermal preparations have been proposed (for example, Patent Documents 1 and 2). In the case of a transdermally absorbable preparation, for example, imidafenacin can be easily administered even to elderly people. In addition, a temporary increase in blood concentration, which may occur in the case of oral administration, can be suppressed.
国際公開第2005/011683号　パンフレットInternational Publication No. 2005/011683 Pamphlet 国際公開第2006/082888号International Publication No. 2006/082888
　一般に、異物の体内への侵入を防ぐ皮膚のバリヤー機能により、経皮投与による場合の薬物の吸収性は経口投与などの場合と比較して低く、経皮吸収型製剤とする場合に薬効発現に必要な血中濃度を確保することは困難な場合が多い。そのため、経皮吸収型製剤の剤形で投与できる薬物は限られている。イミダフェナシンについても皮膚からの吸収性は非常に低く、そのため、経皮吸収型製剤として投与される際の経皮吸収性の改善が求められている。 In general, due to the barrier function of the skin that prevents foreign substances from entering the body, the absorbability of drugs by transdermal administration is lower than that of oral administration, etc. It is often difficult to ensure the necessary blood concentration. Therefore, the drugs that can be administered in the dosage form of the transdermal preparation are limited. Imidafenacin also has very low absorbability from the skin, and therefore, improvement in transdermal absorbability when administered as a transdermally absorbable preparation is required.
　本発明はこのような事情に基づきなされたものであり、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドまたは薬学的に許容可能なその塩について優れた経皮吸収性を示す経皮吸収型製剤を提供することを目的とする。 The present invention has been made based on such circumstances, and has excellent transdermal absorbability with respect to 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof. It aims at providing the percutaneous absorption type formulation which shows this.
　本発明の態様は、例えば以下のとおりである。
　１）支持体と、前記支持体表面に形成され、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミド若しくは薬学的に許容されるその塩を含有するアクリル系粘着剤層とを有し、前記アクリル系粘着剤層に、オレイン酸、および炭素数が2～10であるカルボン酸をさらに含有する経皮吸収型製剤。
　２）前記アクリル系粘着剤層が、カプリン酸およびクロタミトンをさらに含有する１）に記載の経皮吸収型製剤。
　３）前記炭素数が2～10であるカルボン酸が乳酸である1）または2）に記載の経皮吸収型製剤。
　４）前記アクリル系粘着剤層が、炭素数が6～20である脂肪酸のエステルをさらに含有する１）～3）のいずれか１つに記載の経皮吸収型製剤。
　５）前記炭素数が6～20である脂肪酸のエステルがミリスチン酸イソプロピルである4）に記載の経皮吸収型製剤。 Aspects of the present invention are as follows, for example.
1) A support and an acrylic pressure-sensitive adhesive layer formed on the surface of the support and containing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof And the acrylic pressure-sensitive adhesive layer further contains oleic acid and a carboxylic acid having 2 to 10 carbon atoms.
2) The transdermal preparation according to 1), wherein the acrylic pressure-sensitive adhesive layer further contains capric acid and crotamiton.
3) The percutaneous absorption preparation according to 1) or 2), wherein the carboxylic acid having 2 to 10 carbon atoms is lactic acid.
4) The transdermally absorbable preparation according to any one of 1) to 3), wherein the acrylic pressure-sensitive adhesive layer further contains an ester of a fatty acid having 6 to 20 carbon atoms.
5) The transdermal preparation according to 4), wherein the fatty acid ester having 6 to 20 carbon atoms is isopropyl myristate.
　また、本発明の他の態様は、アクリル系粘着剤、オレイン酸、および炭素数が2～10であるカルボン酸を含む、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミド若しくは薬学的に許容されるその塩の経皮吸収を促進する組成物に関する。当該組成物は、例えば、経皮吸収型製剤の粘着剤層を構成する組成物として用いることができる。 In addition, another embodiment of the present invention provides 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyl containing an acrylic pressure-sensitive adhesive, oleic acid, and a carboxylic acid having 2 to 10 carbon atoms The present invention relates to a composition that promotes transdermal absorption of an amide or a pharmaceutically acceptable salt thereof. The said composition can be used as a composition which comprises the adhesive layer of a percutaneous absorption type formulation, for example.
　本発明によれば、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドまたは薬学的に許容可能なその塩について優れた経皮吸収性を示す経皮吸収型製剤を提供することができる。 According to the present invention, there is provided a percutaneous absorption preparation having excellent percutaneous absorption for 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof. can do.
実施例および比較例の経皮吸収型製剤の粘着剤層に含まれる成分の組成を示す表である。It is a table | surface which shows the composition of the component contained in the adhesive layer of the transdermal absorption type formulation of an Example and a comparative example. 実施例および比較例の経皮吸収型製剤のFLUX値を表すグラフである。It is a graph showing the FLUX value of the percutaneous absorption type preparation of an Example and a comparative example.
　以下、本発明の実施形態の１つについて詳細に説明する。 Hereinafter, one embodiment of the present invention will be described in detail.
　本実施形態の経皮吸収型製剤は、支持体と、当該支持体の表面に形成されたアクリル系粘着剤を含有するアクリル系粘着剤層（以下、単に粘着剤層とも称す）とを有する。粘着剤層は、有効成分である4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドまたは薬学的に許容可能なその塩を含有する。 The percutaneous absorption type preparation of this embodiment has a support and an acrylic pressure-sensitive adhesive layer (hereinafter also simply referred to as a pressure-sensitive adhesive layer) containing an acrylic pressure-sensitive adhesive formed on the surface of the support. The pressure-sensitive adhesive layer contains 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof as an active ingredient.
　なお、以下の説明においては、理解を容易とするために、遊離型である4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドと薬学的に許容されるその塩とを総じて、イミダフェナシンと称する。
　また、本明細書において、経皮吸収型製剤とは、皮膚に貼付されて、皮膚を介して薬物を体内に吸収させる医薬の剤形をいう。皮膚を介して体内に導入された薬物は、例えば、毛細血管中に吸収され、血液の流れに従って作用部位に送達される。 In the following description, for ease of understanding, 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide and its pharmaceutically acceptable salt are used in a free form. Collectively called imidafenacin.
Further, in the present specification, the transdermal preparation refers to a pharmaceutical dosage form that is affixed to the skin and absorbs the drug into the body through the skin. Drugs introduced into the body through the skin are absorbed, for example, into capillaries and delivered to the site of action according to blood flow.
　さらに、本明細書においては、有効成分であるイミダフェナシンのほかにアクリル系粘着剤層に配合される成分を総じて、添加剤と称する。添加剤には、オレイン酸、炭素数が2～10であるカルボン酸、および必要に応じて配合される他の成分（カプリン酸およびクロタミトン、炭素数が6～20である脂肪酸のエステル、および／またはその他の成分）が含まれる。
　さらにまた、本明細書において、粘着剤層に含まれる各成分の粘着剤層の全成分に対する割合とは、アクリル系粘着剤、イミダフェナシン、および添加剤からなる粘着剤層の全質量を基準とすることを意味している。但し、基準となる粘着剤層の全質量に、製造時において使用される場合のある有機溶媒は含まれない。 Furthermore, in this specification, the component mix | blended with an acrylic adhesive layer other than the imidafenacin which is an active ingredient is generally called an additive. Additives include oleic acid, carboxylic acids having 2 to 10 carbon atoms, and other ingredients (capric acid and crotamiton, esters of fatty acids having 6 to 20 carbon atoms, and / or as required) Or other ingredients).
Furthermore, in this specification, the ratio of each component contained in the pressure-sensitive adhesive layer to the total components of the pressure-sensitive adhesive layer is based on the total mass of the pressure-sensitive adhesive layer composed of the acrylic pressure-sensitive adhesive, imidafenacin, and additives. It means that. However, the total mass of the reference pressure-sensitive adhesive layer does not include an organic solvent that may be used during production.
　粘着剤層を構成するアクリル系粘着剤については、特に限定されず、当業者がその構成を適宜選択することができる。
　アクリル系粘着剤は、例えば1種のアクリル酸エステルから形成されるアクリル酸エステル単独重合体や、2種以上のアクリル酸エステルから形成される共重合体や、アクリル酸エステルと他の官能性単量体との共重合体、またはこれらの混合物から形成することができる。
　アクリル酸エステルは、例えば、(メタ)アクリル酸メチルエステル、(メタ)アクリル酸エチルエステル、(メタ)アクリル酸ブチルエステル、(メタ)アクリル酸ペンチルエステル、(メタ)アクリル酸ヘキシルエステル、(メタ)アクリル酸ヘプチルエステル、(メタ)アクリル酸オクチルエステル、(メタ)アクリル酸ノニルエステル、または(メタ)アクリル酸デシルエステルなどを用いることができる。アクリル酸エステルと共重合を形成させることができる官能性単量体は、例えば、(メタ)アクリル酸ヒドロキシエチルエステル、(メタ)アクリル酸ヒドロキシプロピルエステルなどのヒドロキシル基含有単量体、(メタ)アクリルアミド、ジメチル(メタ)アクリルアミドなどのアミド基含有単量体、または(メタ)アクリル酸、イタコン酸、またはマレイン酸などのカルボキシル基含有単量体などを用いることができる。
　具体的には、アクリル系粘着剤として、アクリル酸・アクリル酸オクチルエステル共重合体、アクリル酸２－エチルヘキシル・メタクリル酸２－エチルヘキシル・メタクリル酸ドデシル共重合体、またはアクリル酸２－エチルヘキシル・ビニルピロリドン共重合体等を用いることができる。 It does not specifically limit about the acrylic adhesive which comprises an adhesive layer, Those skilled in the art can select the structure suitably.
Acrylic pressure-sensitive adhesives are, for example, acrylic ester homopolymers formed from one type of acrylic ester, copolymers formed from two or more types of acrylic ester, acrylic esters and other functional monomers. It can be formed from a copolymer with a monomer, or a mixture thereof.
Acrylic acid esters are, for example, (meth) acrylic acid methyl ester, (meth) acrylic acid ethyl ester, (meth) acrylic acid butyl ester, (meth) acrylic acid pentyl ester, (meth) acrylic acid hexyl ester, (meth) Acrylic heptyl ester, (meth) acrylic acid octyl ester, (meth) acrylic acid nonyl ester, (meth) acrylic acid decyl ester, or the like can be used. Functional monomers capable of forming a copolymer with an acrylic ester include, for example, hydroxyl group-containing monomers such as (meth) acrylic acid hydroxyethyl ester, (meth) acrylic acid hydroxypropyl ester, (meth) Amide group-containing monomers such as acrylamide and dimethyl (meth) acrylamide, or carboxyl group-containing monomers such as (meth) acrylic acid, itaconic acid, and maleic acid can be used.
Specifically, as an acrylic adhesive, acrylic acid / octyl acrylate ester copolymer, 2-ethylhexyl acrylate / 2-ethylhexyl methacrylate / dodecyl methacrylate copolymer, or 2-ethylhexyl acrylate / vinyl pyrrolidone acrylate A copolymer or the like can be used.
　アクリル系粘着剤の粘着剤層に配合される全成分に対する割合は特に限定されないが、例えば、50～90質量％（好ましくは50～80質量％）とすることができる。 The ratio of the acrylic pressure-sensitive adhesive with respect to all components blended in the pressure-sensitive adhesive layer is not particularly limited, but can be, for example, 50 to 90% by mass (preferably 50 to 80% by mass).
　粘着剤層は、有効成分であるイミダフェナシン、具体的には、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミド若しくは薬学的に許容されるその塩を含む。
　イミダフェナシンは、溶解型、または溶解型と非溶解型との混合のいずれで配合されていてもよい。なお、溶解型とは、粘着剤層においてイミダフェナシンが完全に溶解している状態であることをいい、詳しくは粘着剤層中にイミダフェナシンの結晶が目視または光学顕微鏡で観察されない状態をいう。一方、非溶解型とは、イミダフェナシンが結晶または非結晶の状態で粘着剤層中に存在していることをいう。溶解型であるイミダフェナシンは、皮膚を介して体内に吸収される。また、非溶解型イミダフェナシンは、直接は体内に吸収されないが、経皮吸収に伴って溶解型のイミダフェナシンが減少するに従い、溶解型に変化する。すなわち、非溶解型イミダフェナシンは、溶解型イミダフェナシンの供給源として作用する。
　本実施形態の経皮吸収型製剤においては、粘着剤層に含有されるイミダフェナシンは、速やかな経皮吸収性および皮膚接着性等の品質安定性の観点から溶解型であることが好ましい。
　4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドの薬学的に許容される塩としては、例えば、塩酸塩、硫酸塩、もしくは臭化水素酸塩などの無機酸塩、またはマレイン酸塩、フマル酸塩、酢酸塩、シュウ酸塩、酒石酸塩、またはベンゼンスルホン酸などの有機酸塩が挙げられる。 The pressure-sensitive adhesive layer contains imidafenacin as an active ingredient, specifically, 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof.
Imidafenacin may be blended either in a dissolved form or in a mixture of a dissolved form and a non-dissolved form. The dissolved type means a state in which imidafenacin is completely dissolved in the pressure-sensitive adhesive layer, and specifically refers to a state in which imidafenacin crystals are not observed visually or with an optical microscope in the pressure-sensitive adhesive layer. On the other hand, the non-dissolving type means that imidafenacin is present in the pressure-sensitive adhesive layer in a crystalline or non-crystalline state. The dissolved form of imidafenacin is absorbed into the body through the skin. Insoluble imidafenacin is not directly absorbed into the body, but changes into dissolved form as the dissolved imidafenacin decreases with percutaneous absorption. That is, undissolved imidafenacin acts as a source of dissolved imidafenacin.
In the transdermal preparation of this embodiment, imidafenacin contained in the pressure-sensitive adhesive layer is preferably a dissolution type from the viewpoint of quality stability such as rapid transdermal absorbability and skin adhesiveness.
Examples of pharmaceutically acceptable salts of 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide include inorganic acid salts such as hydrochloride, sulfate, or hydrobromide, Or organic acid salts such as maleate, fumarate, acetate, oxalate, tartrate, or benzenesulfonic acid.
　イミダフェナシンの粘着剤層に配合される全成分に対する割合は特に限定されないが、例えば、1～30質量％（好ましくは2～20質量％）とすることができる。 The ratio of imidafenacin to the total components blended in the pressure-sensitive adhesive layer is not particularly limited, but can be, for example, 1 to 30% by mass (preferably 2 to 20% by mass).
　本実施形態の経皮吸収型製剤において、粘着剤層は、オレイン酸、および炭素数が2～10であるカルボン酸を含有する。オレイン酸、および炭素数が2～10であるカルボン酸を粘着剤層に含有することで、イミダフェナシンの経皮吸収性を高めることができる。 In the transdermal preparation of this embodiment, the pressure-sensitive adhesive layer contains oleic acid and a carboxylic acid having 2 to 10 carbon atoms. By containing oleic acid and a carboxylic acid having 2 to 10 carbon atoms in the adhesive layer, the transdermal absorbability of imidafenacin can be enhanced.
　オレイン酸は、例えば、イミダフェナシンをアクリル系粘着剤に溶解させる溶解剤として作用する。
　炭素数が2～10であるカルボン酸は、オレイン酸と同様に、例えば、溶解剤として作用する。炭素数が2～10であるカルボン酸は、酢酸、プロピオン酸、酪酸、ペンタン酸、またはヘプタン酸等を挙げることができる。さらに、炭素数が2～10であるカルボン酸として、アルコール性またはフェノール性の水酸基を有するカルボン酸であるヒドロキシ酸も用いることができる。ヒドロキシ酸としては、例えば、乳酸、酒石酸、またはクエン酸などを挙げることができる。本実施形態においては、イミダフェナシンの溶解性の観点から、ヒドロキシ酸を用いることが好ましく、乳酸を用いることがさらに好ましい。  Oleic acid acts, for example, as a solubilizer that dissolves imidafenacin in an acrylic adhesive.
The carboxylic acid having 2 to 10 carbon atoms acts as a solubilizer, for example, like oleic acid. Examples of the carboxylic acid having 2 to 10 carbon atoms include acetic acid, propionic acid, butyric acid, pentanoic acid, and heptanoic acid. Further, as the carboxylic acid having 2 to 10 carbon atoms, a hydroxy acid which is a carboxylic acid having an alcoholic or phenolic hydroxyl group can also be used. Examples of the hydroxy acid include lactic acid, tartaric acid, and citric acid. In this embodiment, it is preferable to use a hydroxy acid, and it is more preferable to use lactic acid from the viewpoint of the solubility of imidafenacin.
　オレイン酸、および炭素数が2～10であるカルボン酸の粘着剤層に配合される全成分に対する割合は特に限定されない。例えば、オレイン酸の割合は、粘着剤層に配合される全成分に対して2～20質量％（好ましくは5～15質量％）とすることができる。また、炭素数が2～10であるカルボン酸の割合は、粘着剤層に配合される全成分に対して0.5～30量％（好ましくは1～20質量％）とすることができる。 The ratio of oleic acid and carboxylic acid having 2 to 10 carbon atoms to the total components blended in the adhesive layer is not particularly limited. For example, the proportion of oleic acid can be 2 to 20% by mass (preferably 5 to 15% by mass) with respect to the total components blended in the pressure-sensitive adhesive layer. Further, the proportion of the carboxylic acid having 2 to 10 carbon atoms can be 0.5 to 30% by mass (preferably 1 to 20% by mass) with respect to all the components blended in the pressure-sensitive adhesive layer.
　また、本実施形態の経皮吸収型製剤においては、イミダフェナシンを含有するアクリル系粘着剤層に、オレイン酸、および炭素数が2～10であるカルボン酸に加えて、カプリン酸およびクロタミトンをさらに含有することが好ましい。
　カプリン酸は、オレイン酸や炭素数2～10のカルボン酸と同様に、例えば、溶解剤として作用する。
　また、クロタミトンは、例えば、イミダフェナシンの体内への吸収促進剤として作用する。
　本実施形態においては、カプリン酸およびクロタミトンを粘着剤層に含有することで、イミダフェナシンの経皮吸収性をさらに高めることができる。さらに、より好ましい態様としては、イミダフェナシンを含有する経皮吸収型製剤の粘着剤層は、オレイン酸、乳酸などの炭素数が2～10であるカルボン酸、カプリン酸およびクロタミトンに加えて、後述するミリスチン酸イソプロピルなどの炭素数が6～20である脂肪酸のエステルをさらに含有する。 In addition, in the transdermal preparation of this embodiment, the acrylic adhesive layer containing imidafenacin further contains capric acid and crotamiton in addition to oleic acid and carboxylic acid having 2 to 10 carbon atoms. It is preferable to do.
Capric acid acts as a solubilizer, for example, like oleic acid and carboxylic acids having 2 to 10 carbon atoms.
Moreover, crotamiton acts as an absorption promoter for imidafenacin into the body, for example.
In this embodiment, the transdermal absorbability of imidafenacin can be further enhanced by containing capric acid and crotamiton in the adhesive layer. Further, as a more preferred embodiment, the pressure-sensitive adhesive layer of the transdermal preparation containing imidafenacin is described later in addition to carboxylic acid having 2 to 10 carbon atoms such as oleic acid and lactic acid, capric acid and crotamiton. It further contains an ester of a fatty acid having 6 to 20 carbon atoms, such as isopropyl myristate.
　カプリン酸およびクロタミトンの粘着剤層に配合される全成分に対する割合は特に限定されないが、例えば、カプリン酸の割合は、粘着剤層に配合される全成分に対して0.1～20質量％（好ましくは0.5～15質量％）とすることができる。また、クロタミトンの割合は、粘着剤層に配合される全成分に対して0.1～10質量％（好ましくは0.5～10質量％）とすることができる。 The ratio of capric acid and crotamiton to the total component blended in the pressure-sensitive adhesive layer is not particularly limited. For example, the ratio of capric acid is 0.1 to 20% by mass (preferably, the total component blended in the pressure-sensitive adhesive layer). 0.5 to 15% by mass). The ratio of crotamiton can be 0.1 to 10% by mass (preferably 0.5 to 10% by mass) with respect to the total components blended in the pressure-sensitive adhesive layer.
　さらに、本実施形態の経皮吸収型製剤においては、オレイン酸、および炭素数が2～10であるカルボン酸に加えて、炭素数が6～20である脂肪酸のエステルをイミダフェナシンを含有する粘着剤層にさらに含有することで、粘着剤層の物性を最適化できるとともに、イミダフェナシンの経皮吸収性をより高めることができる。
　炭素数が6～20である脂肪酸のエステルは、例えば、アクリル系粘着剤の粘着性を高める軟化剤として作用する。炭素数が6～20である脂肪酸のエステルは、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、またはオレイン酸オレイル等を挙げることができる。本実施形態においては、ミリスチン酸イソプロピルを用いることが好ましい。炭素数が6～20である脂肪酸のエステルの粘着剤層に配合される全成分に対する割合は2～50質量%、好ましくは5～40質量%とすることができる。 Furthermore, in the transdermally absorbable preparation of this embodiment, in addition to oleic acid and a carboxylic acid having 2 to 10 carbon atoms, an ester of a fatty acid having 6 to 20 carbon atoms contains imidafenacin. By further containing in the layer, the physical properties of the pressure-sensitive adhesive layer can be optimized, and the transdermal absorbability of imidafenacin can be further increased.
An ester of a fatty acid having 6 to 20 carbon atoms acts, for example, as a softening agent that increases the tackiness of an acrylic pressure-sensitive adhesive. Examples of the fatty acid ester having 6 to 20 carbon atoms include isopropyl myristate, isopropyl palmitate, and oleyl oleate. In this embodiment, it is preferable to use isopropyl myristate. The ratio of the fatty acid ester having 6 to 20 carbon atoms to the total components blended in the pressure-sensitive adhesive layer can be 2 to 50% by mass, preferably 5 to 40% by mass.
　本実施形態においては、粘着剤層に添加剤としてさらに他の成分を含んでもよい。他の含有成分としては、例えば、その他の溶解剤、その他の軟化剤、その他の吸収促進剤、皮膚刺激緩和剤、および酸化防止剤のうち１種または２種以上とすることができる。 In the present embodiment, the pressure-sensitive adhesive layer may further contain other components as additives. Examples of other components include one or more of other solubilizers, other softeners, other absorption enhancers, skin irritation mitigators, and antioxidants.
　溶解剤としては、高級脂肪酸エステル（パルミチン酸イソプロピル、もしくはオレイン酸オレイル等）、高級アルコール（ラウリルアルコール、イソプロパノール、イソステアリルアルコール、オクチルドデカノール、もしくはオレイルアルコール等）、脂肪酸（イソステアリン酸、ラウリン酸、アジピン酸、セバシン酸、もしくはミリスチン酸等）、二塩基酸ジエステル類（セバシン酸ジエチル、セバシン酸ジイソプロピル、もしくはアジピン酸ジイソプロピル等）、トリアセチン、ベンジルアルコール、乳酸セチル、乳酸オクチルドデシル、流動パラフィン、またはこれらの２種以上の混合物を挙げることができる。 Soluble agents include higher fatty acid esters (such as isopropyl palmitate or oleyl oleate), higher alcohols (such as lauryl alcohol, isopropanol, isostearyl alcohol, octyldodecanol, or oleyl alcohol), fatty acids (isostearic acid, lauric acid, Adipic acid, sebacic acid, or myristic acid), dibasic acid diesters (diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, etc.), triacetin, benzyl alcohol, cetyl lactate, octyldodecyl lactate, liquid paraffin, or these The mixture of 2 or more types of these can be mentioned.
　軟化剤としては、流動パラフィン等のパラフィン油、スクワラン、スクワレン等の動物油、アーモンド油、オリブ油、ツバキ油、ヒマシ油、トール油、ラッカセイ油等の植物油、シリコーン油、ポリブテン、中鎖脂肪酸トリグリセリド、モノステアリン酸グリセリン、ミリスチン酸イソプロピル、アジピン酸ジイソプロピル、ジプロピレングリコールまたはこれらの２種以上の混合物を挙げることができる。 As softeners, paraffin oil such as liquid paraffin, animal oil such as squalane and squalene, almond oil, olive oil, camellia oil, castor oil, tall oil, peanut oil and other vegetable oils, silicone oil, polybutene, medium chain fatty acid triglyceride, Mention may be made of glyceryl monostearate, isopropyl myristate, diisopropyl adipate, dipropylene glycol or mixtures of two or more thereof.
　吸収促進剤としては、トリアセチン、脂肪酸もしくは脂肪族アルコール類（ラウリン酸、ミリスチン酸、オレイルアルコール、イソプロパノール、ラウリルアルコール、もしくはジプロピレングリコール、プロピレングリコール等）、脂肪酸エステル（グリセリルモノラウレート、グリセリルモノオレエート、乳酸セチル、乳酸オクチルドデシル、グリセロールモノラウレート、グリセロールモノオレート、プロピレングリコールモノラウレート、プロピレングリコールモノオレート、ソルビタンモノラウレート、もしくはソルビタンモノオレート等）、またはこれらの２種以上の混合物を挙げることができる。 Absorption accelerators include triacetin, fatty acids or fatty alcohols (lauric acid, myristic acid, oleyl alcohol, isopropanol, lauryl alcohol, dipropylene glycol, propylene glycol, etc.), fatty acid esters (glyceryl monolaurate, glyceryl monoole) Cetyl lactate, octyl dodecyl lactate, glycerol monolaurate, glycerol monooleate, propylene glycol monolaurate, propylene glycol monooleate, sorbitan monolaurate, or sorbitan monooleate), or a mixture of two or more of these Can be mentioned.
　皮膚刺激緩和剤としては、グリセリン、アラントイン、抗ヒスタミン薬（ジフェンヒドラミン等）、消炎剤（グリチルレチン酸等）、ステロイド薬、またはこれらの２種以上の混合物を挙げることができる。 Examples of the skin irritation mitigating agent include glycerin, allantoin, antihistamines (diphenhydramine, etc.), anti-inflammatory agents (glycyrrhetinic acid, etc.), steroids, or a mixture of two or more of these.
　酸化防止剤としては、ジブチルヒドロキシトルエン（BHT）、DL－α－トコフェロール、アスコルビン酸パルミテート、またはこれらの２種以上の混合物を挙げることができる。 Examples of the antioxidant include dibutylhydroxytoluene (BHT), DL-α-tocopherol, ascorbyl palmitate, or a mixture of two or more thereof.
　さらに他の成分も添加剤として含まれていてもよい。具体的には、例えば、石油樹脂（クイントン、もしくはアルコン等）；界面活性剤（ポリオキシエチレン硬化ヒマシ油２０、ポリオキシエチレン硬化ヒマシ油６０、ポリオキシエチレンソルビット脂肪酸エステル（ポリソルベート２０、ポリソルベート６０、ポリソルベート８０、もしくはポリオキシエチレンソルビタンモノラウレート等）、ポリオキシエチレン脂肪酸エステル（ステアリン酸ポリオキシル４０等）、ソルビタン脂肪酸エステル（モノオレイン酸ソルビタン、トリオレイン酸ソルビタン、モノラウリン酸ソルビタン、もしくはセスキオレイン酸ソルビタン等）、自己乳化型モノステアリン酸グリセリン、モノステアリン酸グリセリン、モノステアリン酸ソルビタン、蔗糖脂肪酸エステル、マクロゴール４００、ラウロマクロゴール、リン酸ナトリウムポリオキシエチレンラウリルエーテル、リン酸ポリオキシエチレンオレイルエーテル、ポリオキシエチレンノニルフェニルエーテル、ポリオキシエチレンオクチルフェニルエーテル、ポリオキシエチレンポリオキシプロピレングリコール（ポリオキシエチレン(120)ポリオキシプロピレン(40)グリコール、ポリオキシエチレン(160)ポリオキシプロピレン(30)グリコール、もしくはポリオキシエチレン(20)ポリオキシプロピレン(20)グリコール等）、ポリオキシエチレンポリオキシプロピレンデシルテトラデシルエーテル、アルキルアリルポリエーテルアルコール、ポリオキシエチレンセチルエーテル、ポリオキシエチレンオレイルアミン、ポリオキシエチレンソルビットミツロウ、ラウリン酸ジエタノールアミド、ステアリルアルコール、二塩基酸ジエステル類（セバシン酸ジエチル等）、スクワラン、セタノール、もしくはセトマクロゴール１０００等）；着香料（ハッカ油、オレンジ油、カミツレ油、スペアミント油、チョウジ油、テレビン油、パインオイル、ヒマラヤスギ油、ベルガモット油、ユーカリ油、ラベンダー油、ローズ油、ローマカミツレ油、ペルーバルサム、ｄ－カンフル、ｄｌ－カンフル、ｄ－ボルネオール、ｄｌ－ボルネオール、ｄｌ－メントール、ｌ－メントール、ゲラニオール、サリチル酸メチル、シンナムアルデヒド、もしくはピペロナール等）、またはこれらの２種以上の混合物が挙げられる。 Furthermore, other components may also be included as additives. Specifically, for example, petroleum resin (Quinton or Alcon etc.); surfactant (polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene sorbite fatty acid ester (polysorbate 20, polysorbate 60, Polysorbate 80 or polyoxyethylene sorbitan monolaurate), polyoxyethylene fatty acid ester (polyoxyl 40 stearate), sorbitan fatty acid ester (sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate, or sorbitan sesquioleate) Etc.), self-emulsifying type glyceryl monostearate, glyceryl monostearate, sorbitan monostearate, sucrose fatty acid ester, macrogol 400, lauromacro Sodium phosphate, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene nonylphenyl ether, polyoxyethylene octylphenyl ether, polyoxyethylene polyoxypropylene glycol (polyoxyethylene (120) polyoxy Propylene (40) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, or polyoxyethylene (20) polyoxypropylene (20) glycol), polyoxyethylene polyoxypropylene decyl tetradecyl ether, alkylallyl Polyether alcohol, polyoxyethylene cetyl ether, polyoxyethylene oleylamine, polyoxyethylene sorbit beeswax, lauric acid diethanolamide, stearyl Alcohol, dibasic acid diesters (diethyl sebacate, etc.), squalane, cetanol, or cetomacrogol 1000, etc .; Cedar oil, bergamot oil, eucalyptus oil, lavender oil, rose oil, roman chamomile oil, peruvian balsam, d-camphor, dl-camphor, d-borneol, dl-borneol, dl-menthol, l-menthol, geraniol, methyl salicylate , Cinnamaldehyde, or piperonal), or a mixture of two or more thereof.
　本実施形態の経皮吸収型製剤は、支持体上にアクリル系粘着剤層を形成することにより製造することができる。また、粘着剤層は、使用されるときまで当該粘着剤層を保護する目的で、剥離ライナーによって覆われることが好ましい。本実施形態の経皮吸収型製剤の製造方法は特に限定されず、当業者が適宜選択することができる。
　例えば、本実施形態の経皮吸収型製剤は、一般にホットメルト法と称される方法や溶媒法と称される方法により製造することができる。
　ホットメルト法に基づく場合は、例えば、イミダフェナシンと、添加剤と、アクリル系粘着剤との混合物（基剤成分）を熱融解させ、剥離フィルムまたは支持体に塗工して粘着剤層を形成する。続いて、形成された粘着剤層に、支持体または剥離フィルムと貼り合わせることにより、経皮吸収型製剤を得る。
　また、溶媒法に基づく場合は、例えば、イミダフェナシンと、添加剤と、アクリル系粘着剤との混合物を、メタノール、エタノール、酢酸エチル、クロロホルム、またはヘキサンなどの有機溶媒に溶解させ、剥離フィルムまたは支持体上に伸展および塗工する。次に、溶媒を乾燥除去して粘着剤層を形成する。続いて、形成された粘着剤層に、支持体または剥離フィルムと貼り合わせることにより、経皮吸収型製剤を得る。
　なお、粘着剤層の大きさや厚みは特に限定されず、当業者が適宜設定することができる。 The transdermal preparation of this embodiment can be produced by forming an acrylic pressure-sensitive adhesive layer on a support. The pressure-sensitive adhesive layer is preferably covered with a release liner for the purpose of protecting the pressure-sensitive adhesive layer until it is used. The manufacturing method of the transdermally absorbable preparation of the present embodiment is not particularly limited, and can be appropriately selected by those skilled in the art.
For example, the transdermally absorbable preparation of this embodiment can be produced by a method generally called a hot melt method or a method called a solvent method.
When based on the hot melt method, for example, a mixture (base component) of imidafenacin, an additive, and an acrylic pressure-sensitive adhesive is melted by heat and applied to a release film or a support to form a pressure-sensitive adhesive layer. . Subsequently, a transdermal preparation is obtained by bonding the formed pressure-sensitive adhesive layer to a support or a release film.
In addition, when based on the solvent method, for example, a mixture of imidafenacin, an additive, and an acrylic pressure-sensitive adhesive is dissolved in an organic solvent such as methanol, ethanol, ethyl acetate, chloroform, or hexane, and a release film or a support is obtained. Extend and apply on the body. Next, the solvent is removed by drying to form an adhesive layer. Subsequently, a transdermal preparation is obtained by bonding the formed pressure-sensitive adhesive layer to a support or a release film.
In addition, the magnitude | size and thickness of an adhesive layer are not specifically limited, Those skilled in the art can set suitably.
　本実施形態の経皮吸収型製剤の支持体の素材は特に限定されず、当業者が適宜設定することができ、例えば伸縮性または非伸縮性の支持体を用いることができる。例えば、布、不織布、ポリウレタン、ポリエステル、ポリ酢酸ビニル、ポリ塩化ビニリデン、ポリエチレン、ポリエチレンテレフタレート（PET）、アルミニウムシート等、またはそれらの複合素材から選択することができる。 The material for the support of the transdermal preparation of the present embodiment is not particularly limited, and can be appropriately set by those skilled in the art. For example, a stretchable or non-stretchable support can be used. For example, it can be selected from cloth, non-woven fabric, polyurethane, polyester, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate (PET), aluminum sheet, or a composite material thereof.
　また剥離フィルムの素材についても特に限定されず、当業者が適宜選択することができる。具体例としては、ポリエチレンフィルム、PETフィルム、またはポリプロピレンフィルムをシリコンコートしたものが挙げられる。 Also, the material of the release film is not particularly limited and can be appropriately selected by those skilled in the art. Specific examples include a polyethylene film, a PET film, or a polypropylene film obtained by silicon coating.
　イミダフェナシンは、膀胱、気管、消化管等の平滑筋のムスカリン受容体のM3およびM1に選択的に拮抗作用を有する。よって、本実施形態の経皮吸収型製剤は、例えば、過活動膀胱（OAB：Over Active Bladder）に伴う頻尿・尿失禁や、喘息、慢性閉塞性肺疾患（COPD：Chronic Obstructive Pulmonary Disease）、または過敏性腸症候群（IBS：Irritable Bowel Syndrome）等の予防薬および／または治療薬として有用である。
　本実施形態の経皮吸収型製剤を用いたイミダフェナシンの投与方法は、予防または治療対象となる疾患や、投与対象となる患者の状態に応じて適宜設定される。例えば、１日２回または１日１回の貼付を行う投与態様とすることができる。また、就寝前や必要な状況が生じる前に貼付を行う投与態様とすることもできる。
　貼付部位は、特に限定されないが、例えば耳の後、腕部、下腹部等の腹部、胸部、背部、腰部、臀部または大腿部内側もしくはふくらはぎ等の脚部などである。 Imidafenacin selectively antagonizes M3 and M1 of muscarinic receptors of smooth muscle such as bladder, trachea and gastrointestinal tract. Therefore, the transdermally absorbable preparation of the present embodiment includes, for example, frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, chronic obstructive pulmonary disease (COPD), Alternatively, it is useful as a preventive and / or therapeutic agent for irritable bowel syndrome (IBS).
The administration method of imidafenacin using the transdermally absorbable preparation of the present embodiment is appropriately set according to the disease to be prevented or treated and the condition of the patient to be administered. For example, it can be set as an administration mode in which application is performed twice a day or once a day. Moreover, it can also be set as the administration aspect which sticks before bedtime or a necessary condition arises.
The affixing site is not particularly limited, and is, for example, the back of the ear, the abdomen such as the arm or lower abdomen, the chest, the back, the waist, the buttocks, the inner side of the thigh, or the legs such as the calf.
　本実施形態において、粘着剤層に含有されるイミダフェナシン量は、特に限定されず、予防または治療の対象となる疾患、粘着剤層の大きさ、投与時間、または目標とされるイミダフェナシンの血中濃度等に応じて設定されるが、例えば、製剤中あるいは１回投与剤中に約0.1mg～約30mgが配合されるようにすることができる。 In the present embodiment, the amount of imidafenacin contained in the pressure-sensitive adhesive layer is not particularly limited, and the disease to be prevented or treated, the size of the pressure-sensitive adhesive layer, the administration time, or the target blood concentration of imidafenacin For example, about 0.1 mg to about 30 mg can be blended in the preparation or in a single dose.
　本実施形態の経皮吸収型製剤によれば、アクリル系粘着剤層にイミダフェナシンとともに、オレイン酸、および炭素数2～10のカルボン酸を含有することで、イミダフェナシンの経皮吸収性を高めることができる。また、粘着剤層にカプリン酸およびクロタミトンを含有することで、イミダフェナシンの経皮吸収性をさらに高めることができる。さらに粘着剤層に炭素数6～20である脂肪酸のエステルを含有することでイミダフェナシンの経皮吸収をより高めることができる。
　このように、イミダフェナシンの経皮吸収性を高めることができる結果、本実施形態の経皮吸収型製剤によれば、例えば、イミダフェナシンを、皮膚を介して循環血中に効率よく吸収させることができる。また、経口投与の場合に見られる急激な血中濃度の上昇に伴って起こり得る副作用も回避することができる。したがって、本実施形態の経皮吸収型製剤は、過活動膀胱（OAB）に伴う頻尿・尿失禁、喘息、COPDまたはIBS等の予防および／または治療薬として大変有用である。 According to the transdermal preparation of this embodiment, the transdermal absorbability of imidafenacin can be improved by containing oleic acid and a carboxylic acid having 2 to 10 carbon atoms in addition to imidafenacin in the acrylic adhesive layer. it can. Moreover, the transdermal absorbability of imidafenacin can be further improved by containing capric acid and crotamiton in the adhesive layer. Furthermore, the transdermal absorption of imidafenacin can be further enhanced by containing an ester of a fatty acid having 6 to 20 carbon atoms in the adhesive layer.
Thus, as a result of improving the transdermal absorbability of imidafenacin, according to the transdermal preparation of this embodiment, for example, imidafenacin can be efficiently absorbed into the circulating blood through the skin. . In addition, side effects that can occur with the rapid increase in blood concentration seen in oral administration can be avoided. Therefore, the transdermally absorbable preparation of this embodiment is very useful as a preventive and / or therapeutic drug for frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, COPD, IBS, and the like.
　以下実施例により本発明をさらに詳しく説明するが、本発明の経皮吸収型製剤は実施例記載の形態のみに限られるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the transdermally absorbable preparation of the present invention is not limited to the form described in the examples.
[実施例1]
　4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミド9g、乳酸3g、オレイン酸7g、カプリン酸0.9gを100gのメタノールに溶解した。この液にミリスチン酸イソプロピル17g、およびクロタミトン2gを添加し、十分に混合し主薬溶液とした。その後、固形濃度20%のアクリル酸・アクリル酸オクチルエステル共重合／酢酸エチル溶液305.5g（粘着剤重量として61.1g）に、主薬溶液を加え、十分に混合し、粘着剤溶液を調製した。粘着剤溶液を75um厚PETフィルムにコンマドクターを用いて、乾燥後の膏体重量が約80g/m2となるよう均一に塗工し、約80℃の温度条件で10分間乾燥して粘着剤層を形成した。形成された粘着剤層と、支持体（15um厚PETフィルム）とを貼り合わせ、実施例1の経皮吸収型製剤とした。 [Example 1]
9 g of 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide, 3 g of lactic acid, 7 g of oleic acid and 0.9 g of capric acid were dissolved in 100 g of methanol. To this solution, 17 g of isopropyl myristate and 2 g of crotamiton were added and mixed well to obtain a main agent solution. Thereafter, the main agent solution was added to 305.5 g of an acrylic acid / octyl acrylate copolymer / ethyl acetate solution having a solid concentration of 20% (61.1 g as the weight of the adhesive) and mixed well to prepare an adhesive solution. Apply the adhesive solution to a 75um PET film using a comma doctor so that the weight of the paste after drying is about 80g / m 2 and dry for 10 minutes at a temperature of about 80 ° C. A layer was formed. The formed pressure-sensitive adhesive layer and a support (15 μm thick PET film) were bonded together to obtain a transdermal absorption preparation of Example 1.
[実施例2～4、および比較例1～14]
　含有される成分の割合を変更したほかは、実施例1と同様の方法により、実施例2～4、および比較例1～14の経皮吸収型製剤を調製した。実施例および比較例において粘着剤層に含まれる成分の量を図1に示す。 [Examples 2 to 4 and Comparative Examples 1 to 14]
Transdermal absorption preparations of Examples 2 to 4 and Comparative Examples 1 to 14 were prepared in the same manner as in Example 1, except that the ratio of the components contained was changed. The amounts of components contained in the pressure-sensitive adhesive layer in Examples and Comparative Examples are shown in FIG.
[In vitroラット皮膚透過性試験方法]
　HWY系雄性ヘアレスラット（10～11週齢）（体重260～280g）の腹部皮膚（φ15mm）を剥離し、真皮側をレセプター層側として、37℃の温水を外周部に循環させたFranz型セル（開口面積：1.77cm２）に装着した。次に皮膚の角質層側に実施例および比較例の各経皮吸収型製剤（φ14mm）を貼付した。レセプター液にはPBS緩衝溶液（pH7.4）を用い、経時的に当該レセプター液をサンプリングした。
　サンプリングしたレセプター液中の イミダフェナシン濃度を、以下の測定条件で、UPLC（Ultra Performance Liquid Chromatography）法により測定した。 [In vitro rat skin permeability test method]
Franz-type cell in which the abdominal skin (φ15mm) of HWY male hairless rats (10-11 weeks old) (weight 260-280g) was peeled off, and 37 ° C hot water was circulated around the outer periphery with the dermis side as the receptor layer side (Open area: 1.77 cm 2 ). Next, the percutaneous absorption preparations (φ14 mm) of Examples and Comparative Examples were attached to the stratum corneum side of the skin. A PBS buffer solution (pH 7.4) was used as the receptor solution, and the receptor solution was sampled over time.
The concentration of imidafenacin in the sampled receptor fluid was measured by the UPLC (Ultra Performance Liquid Chromatography) method under the following measurement conditions.
（UPLC条件）
注入量　：　7.5μL
検出器　：　紫外吸光光度計（測定波長：222nm）
カラム　：　AQUITY UPLC BEH C8　2.1×50mm　（1.7μm）　，Waters製
カラム温度　：　30℃
移動相　：　A液；1000倍希釈したリン酸900mLおよびHPLC用テトラヒドロフラン100mL
　　　　　　B液；10%メタノール
A液 ： B液 ＝850 : 150
流量　　：　約0.7mL/min （イミダフェナシンの保持時間約0.8min） (UPLC condition)
Injection volume: 7.5μL
Detector: Ultraviolet absorptiometer (measurement wavelength: 222nm)
Column: AQUITY UPLC BEH C8 2.1 × 50mm (1.7μm), Waters column temperature: 30 ℃
Mobile phase: Liquid A: 900 mL of phosphoric acid diluted 1000 times and 100 mL of tetrahydrofuran for HPLC
Liquid B: 10% methanol
Liquid A: Liquid B = 850: 150
Flow rate: Approximately 0.7mL / min (Imidafenacin retention time approximately 0.8min)
　測定結果から、各採取ポイントにおける製剤1cm2あたりの累積薬物透過量を算出し（μg/cm2）、時間－累積薬物透過量の関係をグラフ化した。その後、当該グラフから累積薬物透過量の相関直線を算出し、その傾きを薬物透過速度であるFLUX値とした。
（FLUX　：　貼付後、製剤1cm2の面積から経皮吸収する1時間あたりの経皮薬物吸収量） From the measurement results, the cumulative drug permeation amount per 1 cm 2 of the preparation at each sampling point was calculated (μg / cm 2 ), and the relationship between time and cumulative drug permeation amount was graphed. Thereafter, a correlation line of the cumulative drug permeation amount was calculated from the graph, and the slope thereof was defined as a FLUX value that is a drug permeation rate.
(FLUX: Amount of transdermal drug absorbed per hour that is transdermally absorbed from an area of 1 cm 2 of the formulation after application)
　得られたFLUX値を図2に示す。
　実施例1のFLUX値は、実施例1が16.46μg/cm2/hour、実施例2が13.09μg/cm2/hour、実施例3が12.08μg/cm2/hour、および実施例4が11.82μg/cm2/hourである一方、比較例は最も高いFLUX値でも9.81μg/cm2/hourであった（比較例13）。
　実施例1～4の経皮吸収型製剤は、比較例の経皮吸収型製剤と比較して、いずれも高いイミダフェナシンの経皮吸収性を示した。特に、カプリン酸およびクロタミトンを含有する実施例1の経皮吸収型製剤において、他の実施例よりもさらに高い経皮吸収性が確認された。 The obtained FLUX value is shown in FIG.
The FLUX value of Example 1, Example 1 16.46μg / cm 2 / hour, Example 2 13.09μg / cm 2 / hour, is Example 3 12.08μg / cm 2 / hour, and Example 4 is 11.82 While it was μg / cm 2 / hour, the comparative example had a highest FLUX value of 9.81 μg / cm 2 / hour (Comparative Example 13).
The percutaneous absorption preparations of Examples 1 to 4 all showed higher imidafenacin percutaneous absorption than the percutaneous absorption preparation of the comparative example. In particular, the percutaneous absorption preparation of Example 1 containing capric acid and crotamiton was confirmed to have a higher percutaneous absorption than the other Examples.
　本発明の経皮吸収型製剤は、例えば、過活動膀胱（OAB）に伴う頻尿・尿失禁や、喘息、慢性閉塞性肺疾患（COPD）、および過敏性腸症候群（IBS）等の予防および／または治療に有用である。 The transdermally absorbable preparation of the present invention can prevent, for example, frequent urination / urinary incontinence associated with overactive bladder (OAB), asthma, chronic obstructive pulmonary disease (COPD), and irritable bowel syndrome (IBS). Useful for treatment.

Claims (5)

  1. 　支持体と、
    　前記支持体の表面に形成され、4－（2－メチル－1－イミダゾリル）－2，2－ジフェニルブチルアミドまたは薬学的に許容可能なその塩を含有するアクリル系粘着剤層と、を有し、
    　前記アクリル系粘着剤層は、オレイン酸および炭素数が2～10であるカルボン酸をさらに含有する経皮吸収型製剤。     A support;
    An acrylic pressure-sensitive adhesive layer formed on the surface of the support and containing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutyramide or a pharmaceutically acceptable salt thereof. ,
    The acrylic pressure-sensitive adhesive layer is a transdermally absorbable preparation further containing oleic acid and a carboxylic acid having 2 to 10 carbon atoms.
  2. 　前記アクリル系粘着剤層が、カプリン酸およびクロタミトンをさらに含有する請求項１に記載の経皮吸収型製剤。 The transdermal preparation according to claim 1, wherein the acrylic pressure-sensitive adhesive layer further contains capric acid and crotamiton.
  3. 　前記炭素数が2～10であるカルボン酸が乳酸である請求項1または2に記載の経皮吸収型製剤。 3. The transdermal preparation according to claim 1 or 2, wherein the carboxylic acid having 2 to 10 carbon atoms is lactic acid.
  4. 　前記アクリル系粘着剤層が、炭素数が6～20である脂肪酸のエステルをさらに含有する請求項1～3のいずれか１つに記載の経皮吸収型製剤。 The percutaneous absorption preparation according to any one of claims 1 to 3, wherein the acrylic pressure-sensitive adhesive layer further contains an ester of a fatty acid having 6 to 20 carbon atoms.
  5. 　前記炭素数が6～20である脂肪酸のエステルがミリスチン酸イソプロピルである請求項4に記載の経皮吸収型製剤。 5. The transdermal preparation according to claim 4, wherein the fatty acid ester having 6 to 20 carbon atoms is isopropyl myristate.
PCT/JP2012/006829 2011-10-26 2012-10-25 Transdermally absorbed preparation WO2013061588A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013540656A JP5995112B2 (en) 2011-10-26 2012-10-25 Transdermal preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-234921 2011-10-26
JP2011234921 2011-10-26

Publications (1)

Publication Number Publication Date
WO2013061588A1 true WO2013061588A1 (en) 2013-05-02

Family

ID=48167439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/006829 WO2013061588A1 (en) 2011-10-26 2012-10-25 Transdermally absorbed preparation

Country Status (3)

Country Link
JP (1) JP5995112B2 (en)
TW (1) TW201332592A (en)
WO (1) WO2013061588A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014214109A (en) * 2013-04-24 2014-11-17 杏林製薬株式会社 Patch

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1652523A1 (en) * 2003-08-04 2006-05-03 Kyorin Pharmaceutical Co., Ltd. Transdermal absorption preparation
EP1844773A1 (en) * 2005-02-03 2007-10-17 Kyorin Pharmaceutical Co., Ltd. Percutaneous absorption preparation
WO2012057212A1 (en) * 2010-10-28 2012-05-03 久光製薬株式会社 Percutaneous absorption type formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1652523A1 (en) * 2003-08-04 2006-05-03 Kyorin Pharmaceutical Co., Ltd. Transdermal absorption preparation
EP1844773A1 (en) * 2005-02-03 2007-10-17 Kyorin Pharmaceutical Co., Ltd. Percutaneous absorption preparation
WO2012057212A1 (en) * 2010-10-28 2012-05-03 久光製薬株式会社 Percutaneous absorption type formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014214109A (en) * 2013-04-24 2014-11-17 杏林製薬株式会社 Patch

Also Published As

Publication number Publication date
JP5995112B2 (en) 2016-09-21
JPWO2013061588A1 (en) 2015-04-02
TW201332592A (en) 2013-08-16

Similar Documents

Publication Publication Date Title
JP5020061B2 (en) Transdermal preparation
JP5403948B2 (en) Memantine-containing transdermal absorption preparation
WO2013005760A1 (en) Adhesive skin patch containing serotonin receptor antagonist drug
JP6129632B2 (en) Patch
US20080188509A1 (en) Transdermal Preparations and Method for Relieving Side Effects in Pergolide Therapy
JP2006016382A (en) Adhesive patch
WO2016080533A1 (en) Percutaneous absorption agent
JP5995112B2 (en) Transdermal preparation
WO2010098230A1 (en) Transdermal preparation
JP6729584B2 (en) Transdermal patch
JP5091472B2 (en) Adhesives and patches
JP4283507B2 (en) Patch for transdermal administration
JP6104230B2 (en) Transdermal preparation
WO2010098261A1 (en) Risperidone-containing transdermal preparation and adhesive patch using same
JP6695571B2 (en) Transdermal formulation
JP6675589B2 (en) Transdermal formulation
WO2016208729A1 (en) Nalfurafine-containing percutaneous absorption patch
JP6459148B2 (en) Transdermal preparation
WO2017057541A1 (en) Transdermal absorption preparation
JP2016216384A (en) Percutaneous absorption type preparation
JP2017007994A (en) Percutaneous absorption-type preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12842870

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013540656

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12842870

Country of ref document: EP

Kind code of ref document: A1